image credit: Adobe Stock

NICE approves funding for Novartis gene therapy

March 16, 2023

NICE has published final draft guidance regarding the recommendation of routine NHS funding for onasemnogene abeparvovec.

The treatment is a potentially curative one-off gene therapy for treating a rare genetic condition, spinal muscular atrophy (SMA). It will be used specifically among babies aged up to 12 months, before they develop symptoms.

The drug – also known as Zolgensma – is produced by Novartis Gene Therapies. The recommendation has emerged after NICE reviewed the evidence to determine whether it should be available for routine NHS funding in England and Wales.

Read More on Pharma Times